Investigation of the effect of oral L-arginine on pulmonary hypertension in patients with thalassemia major

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191218045785N1

Enrollment

Registered

2020-01-18

Start date

2019-05-13

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta thalassemia.

Interventions

Intervention group: Fifty patients with thalassemia major or intermedia are selected based on inclusion criteria. Due to the limited sample size, this study was designed as a pre- and post-test. All p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Major or intermedia thalassemia with PAP> 30 Systemic blood pressure over 60/90

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pulmonary arterial pressure. Timepoint: Baseline (before intervention) and 6 and 30 days after L-arginine administration. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Systemic blood pressure. Timepoint: Baseline (before intervention) and 6 and 30 days after L-arginine administration. Method of measurement: Blood pressure monitor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLale Najar

Shahre-kord University of Medical Sciences

najarlale@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026